Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 9/20 | 0.65 |
| ▸ | TFPI | P10646 | 1/20 | 0.57 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.56 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31060486 | 0.88 | OPRL1 (0.69) | OPRL1TFPI | |
| SCHEMBL30130109 | 0.87 | TFPI (0.64) | OPRL1TFPI | |
| Nociceptin SCHEMBL29356402 | 0.85 | OPRL1 (0.66) | OPRL1TFPI | |
| SCHEMBL28918838 | 0.85 | OPRL1 (0.70) | OPRL1TFPI | |
| SCHEMBL31719706 | 0.82 | TFPI (0.65) | OPRL1TFPI | |
| Nociceptin-Nh2 SCHEMBL30033176 | 0.80 | OPRL1 (0.79) | OPRL1TFPI | |
| SCHEMBL18047569 | 0.80 | TFPI (0.55) | OPRL1TFPIOPRM1OPRD1OPRK1 | |
| SCHEMBL29531101 | 0.79 | TFPI (0.69) | TFPI | |
| SCHEMBL31504570 | 0.79 | TFPI (0.67) | OPRL1TFPIOPRM1OPRD1OPRK1 | |
| Neuropeptide S SCHEMBL29464558 | 0.79 | TFPI (0.61) | OPRL1TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085826-A1 | ACTIVATION OF ORL1: A NOVEL THERAPY TO PREVENT HEART FAILURE PROGRESSION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-24 | — | — | WO | claimed |
| CN-120130099-A | Conditional handoff enhancement with candidate target cell prioritization | 苹果公司 | 2025-06-10 | — | — | CN | disclosed |
| WO-2025085826-A1 | ACTIVATION OF ORL1: A NOVEL THERAPY TO PREVENT HEART FAILURE PROGRESSION | BAYLOR COLLEGE OF MEDICINE (US) | 2025-04-24 | — | — | WO | disclosed |
| EP-4455145-A2 | PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS | Astraea Therapeutics, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240059664-A1 | Piperidinyl Nociceptin Receptor Compounds | ASTRAEA THERAPEUTICS, LLC | 2024-02-22 | — | — | US | disclosed |
| US-RE49825-E1 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2024-02-06 | — | — | US | disclosed |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2023-12-07 | — | — | US | disclosed |
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | ASTRAEA THERAPEUTICS, LLC (US) | 2023-11-28 | — | — | US | disclosed |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | DMK PHARMACEUTICALS CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | DMK PHARMACEUTICALS CORPORATION | 2022-07-21 | — | — | US | disclosed |
| US-11352422-B2 | Opioid receptor binding agents and uses thereof | VIB VZW (BE) | 2022-06-07 | — | — | US | disclosed |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | VERSI GROUP, LLC (US) | 2022-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827617-B2 | Piperidinyl nociceptin receptor compounds | OPRL1, OPRK1, OPRM1 | OPRL1 1/4885TFPI 3778/4885OPRM1 3/4885 |
| US-11779581-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | OPRL1 4/4885TFPI 2160/4885OPRM1 1/4885 |
| US-20230390281-A1 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | OPRL1 4/4885TFPI 2370/4885OPRM1 1/4885 |
| US-20220226312-A1 | OPIOID FOR USE TO REDUCE AND/OR TREAT DRUG ADDICTION | OPRM1, OPRK1, OPRD1 | OPRL1 4/4885TFPI 2160/4885OPRM1 1/4885 |
| US-20240059664-A1 | Piperidinyl Nociceptin Receptor Compounds | OPRL1, OPRK1, OPRM1 | OPRL1 1/4885TFPI 3778/4885OPRM1 3/4885 |
| US-11246865-B2 | Opioid for use to reduce and/or treat drug addiction | OPRM1, OPRK1, OPRD1 | OPRL1 4/4885TFPI 2160/4885OPRM1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.